Cornerstone Planning Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cornerstone Planning Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.72K	Sell	634 -24	-4%	-$383	﹤0.01%	900
2026 Q1	$10.6K	Sell	658 -122	-16%	-$1.78K	﹤0.01%	875
2025 Q4	$11.4K	Hold	780	–	–	﹤0.01%	766
2025 Q3	$9.45K	Hold	780	–	–	﹤0.01%	793
2025 Q2	$9.13K	Hold	780	–	–	﹤0.01%	580
2025 Q1	$6.31K	Hold	780	–	–	﹤0.01%	668
2024 Q4	$6.44K	Hold	780	–	–	﹤0.01%	527
2024 Q3	$5.84K	Hold	780	–	–	﹤0.01%	539
2024 Q2	$4.19K	Buy	780 +473	+154%	+$2.49K	﹤0.01%	615
2024 Q1	$1.57K	Buy	+307	New	+$2.08K	﹤0.01%	706

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NFG

Norris Financial Group Greenville, South Carolina $251M AUM 48.4% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Cornerstone Planning Group's AUPH Position: Q2 2026 in Review

Cornerstone Planning Group reduced its Aurinia Pharmaceuticals (AUPH) stake by 3.6% in Q2 2026, selling an estimated $383 and leaving 634 shares worth $9.72K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

Cornerstone Planning Group first reported a position in AUPH in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.4K in Q4 2025. 124 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Cornerstone Planning Group held 634 shares of Aurinia Pharmaceuticals worth $9.72K as of Q2 2026.
Cornerstone Planning Group sold 24 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $383.
Aurinia Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #900 holding.
Cornerstone Planning Group first reported a position in Aurinia Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Cornerstone Planning Group's Aurinia Pharmaceuticals position peaked at $11.4K in Q4 2025.
124 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.